

July 13, 2022

Company: Chiome Bioscience Inc.
Representative: Shigeru Kobayashi, President & CEO
(Code: 4583, Tokyo Stock Exchange Growth)

Announcement of target-specific research and option agreement with Heidelberg Pharma

Chiome Bioscience Inc. announced today that the target-specific research and option agreement has been concluded with Heidelberg Pharma. Under this agreement, our therapeutic anti-CDCP1 antibody called PCDC will be granted access to the ATAC[®] platform, Heidelberg Pharma's antibody targeted amanitin conjugate technology.

Amanitin is a toxin found in several species of mushrooms. With ATAC[®] platform, amanitin is conjugated to our anti-CDCP1 antibody. In the preclinical study, the amanitin conjugated anti-CDCP1 antibody has shown significant anti-tumor activities *in vitro* and *in vivo*.

Under this agreement, we will further reinforce the data package of PCDC and accelerate our out-licensing activities.

We also have the right to sublicense the anti-CDCP1 amanitin conjugated antibody. If it is determined that the antibody using ATAC[®] will be out licensed to third parties, we will pay a portion of the revenue received to Heidelberg Pharma.

Upon this conclusion of this agreement, we will pay license fees to Heidelberg Pharma. However, the impact on R & D expenses for the fiscal year ended December 2022 is minor.

<About Heidelberg Pharma>

Heidelberg Pharma is located in Ladenburg, Germany, founded in 1997, and is listed on the Frankfurt Stock Exchange (Symbol: HPHA). It is the first company to develop the toxin amanitin into cancer therapies using its proprietary ATAC[®] technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. The company actively apply this platform to multiple targets in both inhouse project and third-party collaboration. ATAC[®] platform is EU registered trademark of Heidelberg Pharma. (<http://www.heidelberg-pharma.com/>)

<About PCDC>

PCDC is the humanized antibody that targets specific to CDCP1 expressing multiple tumors. Chiome Bioscience develop PCDC as one of our therapeutic pipelines and have completed patent applications for this antibody. We are currently actively working to make a license agreement for this antibody.

【Inquiries】

Chiome Bioscience Inc. Investor Relations
E-mail: ir@chiome.co.jp